Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer
Abstract
Recent studies posit a role for non-coding RNAs in epithelial ovarian cancer (EOC). Combining small RNA sequencing from 179 human serum samples with a neural network analysis produced a miRNA algorithm for diagnosis of EOC (AUC 0.90; 95% CI: 0.81-0.99). The model significantly outperformed CA125 and functioned well regardless of patient age, histology, or stage. Among 454 patients with various diagnoses, the miRNA neural network had 100% specificity for ovarian cancer. After using 325 samples to adapt the neural network to qPCR measurements, the model was validated using 51 independent clinical samples, with a positive predictive value of 91.3% (95% CI: 73.3% - 97.6%) and negative predictive value of 78.6% (95% CI: 64.2% - 88.2%). Finally, biologic relevance was tested using in situ hybridization on 30 pre-metastatic lesions, showing intratumoral concentration of relevant miRNAs. These data suggest circulating miRNAs have potential to develop a non-invasive diagnostic test for ovarian cancer.
Data availability
Article and author information
Author details
Funding
Robert and Deborah First Family Fund
- Kevin M Elias
- Ross S Berkowitz
- Dipanjan Chowdhury
U.S. Department of Defense (OC093426)
- Panagiotis Konstantinopoulos
Honorable Tina Brozman Foundation
- Kevin M Elias
- Dipanjan Chowdhury
U.S. Department of Defense (OC140632)
- Panagiotis Konstantinopoulos
National Institutes of Health (K12HD13015)
- Kevin M Elias
Ruth N White Research Fellowship in Gynecologic Oncology
- Kevin M Elias
- Stephen J Fiascone
Saltonstall Research Fund
- Kevin M Elias
- Stephen J Fiascone
- Ross S Berkowitz
Potter Research Fund
- Kevin M Elias
- Stephen J Fiascone
- Ross S Berkowitz
Sperling Family Fund Fellowship
- Kevin M Elias
- Stephen J Fiascone
- Ross S Berkowitz
Bach Underwood Fund
- Kevin M Elias
- Stephen J Fiascone
- Ross S Berkowitz
First TEAM grant of the foundation for Polish Science and the Smart Growth Operational Programme of the European Union
- Wojciech Fendler
National Institutes of Health (P50CA105009)
- Allison F Vitonis
- Daniel W Cramer
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: All samples were collected after signed informed consent according to locally-approved Institutional Review Board protocols. These studies were approved by the Dana-Farber Cancer Institute Institutional Review Board Protocol 05-060 (NECC study), Brigham and Women's Hospital Institutional Review Board Protocol 2000-P-001678 (Pelvic Mass Protocol), and Dana-Farber/Harvard Cancer Center Institutional Review Board Protocol 12-532 (ERASMOS).
Copyright
© 2017, Elias et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 8,524
- views
-
- 1,188
- downloads
-
- 138
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.